Cite

    Shah, S. et al. (2021). Myeloablative haploidentical t‐cell replete hematopoietic cell transplantation with post‐transplant cyclophosphamide in high‐risk hematological malignancies: Bending the learning curve in a middle‐income setting. Advances in cell and gene therapy. 4 (2), p. n/a. [Online].